Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
Hanley MJ, Kerstein D, Tugnait M, Narasimhan N, Marbury TC, Venkatakrishnan K, Gupta N. Hanley MJ, et al. Among authors: kerstein d. Invest New Drugs. 2023 Jun;41(3):402-410. doi: 10.1007/s10637-023-01339-6. Epub 2023 Apr 13. Invest New Drugs. 2023. PMID: 37052729 Free PMC article.
Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M, Gupta N, Hanley MJ, Sonnichsen D, Kerstein D, Dorer DJ, Venkatakrishnan K, Narasimhan N. Tugnait M, et al. Among authors: kerstein d. Clin Pharmacol Drug Dev. 2020 Feb;9(2):214-223. doi: 10.1002/cpdd.723. Epub 2019 Jul 9. Clin Pharmacol Drug Dev. 2020. PMID: 31287236 Free PMC article. Clinical Trial.
Effect of severe renal impairment on the pharmacokinetics of brigatinib.
Gupta N, Hanley MJ, Kerstein D, Tugnait M, Narasimhan N, Marbury TC, Venkatakrishnan K. Gupta N, et al. Among authors: kerstein d. Invest New Drugs. 2021 Oct;39(5):1306-1314. doi: 10.1007/s10637-021-01095-5. Epub 2021 Mar 20. Invest New Drugs. 2021. PMID: 33742299 Free PMC article. Clinical Trial.
Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Exposure-Response Analyses of Pivotal ALTA Study.
Gupta N, Wang X, Offman E, Rich B, Kerstein D, Hanley M, Diderichsen PM, Zhang P, Venkatakrishnan K. Gupta N, et al. Among authors: kerstein d. CPT Pharmacometrics Syst Pharmacol. 2020 Dec;9(12):718-730. doi: 10.1002/psp4.12569. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 33185028 Free PMC article. Clinical Trial.
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Gettinger SN, et al. Among authors: kerstein d. Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8. Lancet Oncol. 2016. PMID: 27836716 Clinical Trial.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Camidge DR, et al. Among authors: kerstein d. N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280657 Free article. Clinical Trial.
27 results